Ipatasertib - CAS 1001264-89-6
Catalog number: 1001264-89-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C24H32ClN5O2
Molecular Weight:
458.0
COA:
Inquire
Targets:
Akt
Description:
Ipatasertib, also known as GDC-0068 is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GDC-0068 binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.
Appearance:
Solid powder
Synonyms:
GDC-0068; GDC0068; GDC 0068; RG7440; RG-7440; RG 7440; Ipatasertib
MSDS:
Inquire
InChIKey:
GRZXWCHAXNAUHY-NSISKUIASA-N
InChI:
InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1
Canonical SMILES:
CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O
Current Developer:
Genentech/Array BioPharma Inc.
1.Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.
Lin J;Sampath D;Nannini MA;Lee BB;Degtyarev M;Oeh J;Savage H;Guan Z;Hong R;Kassees R;Lee LB;Risom T;Gross S;Liederer BM;Koeppen H;Skelton NJ;Wallin JJ;Belvin M;Punnoose E;Friedman LS;Lin K Clin Cancer Res. 2013 Apr 1;19(7):1760-72. doi: 10.1158/1078-0432.CCR-12-3072. Epub 2013 Jan 3.
PURPOSE: ;We describe the preclinical pharmacology and antitumor activity of GDC-0068, a novel highly selective ATP-competitive pan-Akt inhibitor currently in clinical trials for the treatment of human cancers.;EXPERIMENTAL DESIGN: ;The effect of GDC-0068 on Akt signaling was characterized using specific biomarkers of the Akt pathway, and response to GDC-0068 was evaluated in human cancer cell lines and xenograft models with various genetic backgrounds, either as a single agent or in combination with chemotherapeutic agents.;RESULTS: ;GDC-0068 blocked Akt signaling both in cultured human cancer cell lines and in tumor xenograft models as evidenced by dose-dependent decrease in phosphorylation of downstream targets. Inhibition of Akt activity by GDC-0068 resulted in blockade of cell-cycle progression and reduced viability of cancer cell lines. Markers of Akt activation, including high-basal phospho-Akt levels, PTEN loss, and PIK3CA kinase domain mutations, correlate with sensitivity to GDC-0068. Isogenic PTEN knockout also sensitized MCF10A cells to GDC-0068. In multiple tumor xenograft models, oral administration of GDC-0068 resulted in antitumor activity ranging from tumor growth delay to regression.
2.Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB;Han HS;Gradishar WJ Breast Cancer Res Treat. 2018 Jun;169(3):397-406. doi: 10.1007/s10549-018-4697-y. Epub 2018 Feb 7.
PURPOSE: ;Triple-negative breast cancer (TNBC) accounts for approximately 20% of breast cancer cases. Although there have been advances in the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancers, targeted therapies for TNBC remain unavailable. In this narrative review, we summarize recent discoveries related to the underlying biology of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway in TNBC, examine clinical progress to date, and suggest rational future approaches for investigational therapies in TNBC.;RESULTS: ;As with other subtypes of breast cancer, aberrations in the PI3K/AKT/mTOR pathway are common in TNBC. Preclinical data support the notion that these aberrations predict TNBC inhibition by targeted agents. In a recently published phase 2 clinical trial, an AKT inhibitor (ipatasertib) improved outcomes in a subset of patients with metastatic TNBC when combined with paclitaxel in the first-line setting. In addition, new compounds with distinct specificity and potency targeting different PI3K/AKT/mTOR components and cognate molecules (e.g., mitogen-activated protein kinase) are being developed.
3.Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.
Morgillo F;Della Corte CM;Diana A;Mauro CD;Ciaramella V;Barra G;Belli V;Franzese E;Bianco R;Maiello E;de Vita F;Ciardiello F;Orditura M Oncotarget. 2017 Aug 22;8(44):76479-76491. doi: 10.18632/oncotarget.20385. eCollection 2017 Sep 29.
Purpose: ;The Phosphatidylinositol 3-kinase (PI3Ks) pathway is commonly altereted in breast cancer patients, but its role is still unclear. Taselisib, a mutant PI3Kα selective inhibitor, and ipatasertib, an AKT inhibitor, are currently under investigation in clinical trials in combination with paclitaxel or hormonal therapies in breast cancer. The aim of this study was to evaluate if PI3K or AKT inhibition can prevent resistance to chemotherapy and potentiate its efficacy.;Experimental design: ;The efficacy of combined treatment of ipatasertib and taselisib plus vinorelbine or paclitaxel or eribulin was evaluated ;in vitro; on human breast cancer cells (with different expression profile of hormonal receptors, HER2, and of PI3Ka mutation) on cell survival by using MTT (3,(4,5-dimethylthiazol-2)2,5 difeniltetrazolium bromide) and colony forming assays on cell apoptosis by flow-cytometry analysis. We also investigated the effect of combined treatment on downstream intracellular signaling, by western blot analysis, and on metastatic properties, by migration assays. Finally, we analyzed changes in cell cytoskeleton by immunofluorescence.;Results: ;A significant synergism of ipatasertib or taselisib plus anti-microtubule chemotherapy in terms of anti-proliferative, pro-apoptotic and anti-metastatic effect was observed.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Akt Products


CAS 925681-41-0 10-DEBC hydrochloride

10-DEBC hydrochloride
(CAS: 925681-41-0)

10-DEBC hydrochloride is a selective and reversible Akt/PKB inhibitor suppressing the IGF-1-stimulated phosphorylation and activation of Akt (complete inhibitio...

CAS 522-17-8 Deguelin

Deguelin
(CAS: 522-17-8)

Deguelin is a naturally occurring rotenoid, is known to be an Akt inhibitor and to have an anti-tumor effect on several cancers.

CAS 1396257-94-5 GDC-0068 dihydrochloride

GDC-0068 dihydrochloride
(CAS: 1396257-94-5)

Testing against a broad panel of 230 kinases, GDC-0068 only inhibits 3 kinases by >70% at 1 μM concentration (PRKG1α, PRKG1β, and p70S6K, with IC50 of 98 nM, 69...

CAS 1143532-39-1 AZD-5363

AZD-5363
(CAS: 1143532-39-1)

AZD5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AZD5363 binds to ...

CAS 1047634-65-0 Uprosertib

Uprosertib
(CAS: 1047634-65-0)

Uprosertib, also known as GSK2141795 and GSK795, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potentia...

XL-418
(CAS: 871343-09-8)

XL-418 is a 70 kDa ribosomal protein S6 kinase and Proto oncogene protein c-akt inhibitor. It can inhibit the activities of PKB and p70S6K, both acting downstre...

CAS 1032349-93-1 MK-2206

MK-2206
(CAS: 1032349-93-1)

MK-2206 is an allosteric inhibitor of Akt that prevents translocation of Akt to membranes. It is also an orally bioavailable allosteric inhibitor of the serine/...

CAS 1047644-62-1 Afuresertib

Afuresertib
(CAS: 1047644-62-1)

Afuresertib, also known as GSK2110183,  is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineo...

Chemical Structure

CAS 1001264-89-6 Ipatasertib

Quick Inquiry

Verification code

Featured Items